A Novel Cell-Based Assay For Ubiquitin Drug Discovery

Ubiquitin ligases, particularly E3 ligases, are crucial therapeutic targets implicated in various conditions like viral infections, neurodegenerative diseases, and cancer. Despite their significance, drug discovery in this area has lagged due to the complexity of the ubiquitin system and a lack of high-throughput screening assays. Traditional cell-free assays are labor-intensive and lack biological context, while developing stable cell lines for cell-based assays is challenging and time-consuming. This application note details a novel, high-throughput, cell-based Ubiquitin Ligase Profiling (ULP) assay that addresses these challenges.

This new method streamlines assay development by enabling the rapid preparation of transiently transfected, assay-ready cell banks. Discover how this approach can accelerate E3 ligase drug discovery.